Skip to main content
ATHXinactive

ATHERSYS, INC / NEW

Biopharma developer (SEC filing verified)·Phase 2·CEO: Dear Fellow Stockholders

ATHX evidence brief

What we can confirm

BioSniper Score:
4.7 / 10
Lead Asset:
multistem (Phase 2)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 4.7 / 10 · Lead Asset: multistem (Phase 2)
BioSniper AIPage evidence connected

Prepared research question

What matters most for ATHX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

4.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

multistem (Phase 2)

Next Catalyst

—

Tracking 1 pipeline candidate for ATHERSYS, INC / NEW.

Run ATHERSYS, INC / NEW through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available ATHERSYS, INC / NEW facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is ATHERSYS, INC / NEW's lead drug candidate?

ATHERSYS, INC / NEW's most advanced tracked candidate is multistem (Phase 2) for Traumatic injuries.

Who is the CEO of ATHERSYS, INC / NEW?

Dear Fellow Stockholders is the chief executive officer of ATHERSYS, INC / NEW (ATHX).

923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.